Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?
International Ophthalmology · 2024
DOI: 10.1007/s10792-024-02963-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Ophthalmology, 2024. Verfasst von Cemal Ozsaygılı und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Health Sciences, Kayseri City Training and Research Hospital, Kocasinan, Kayseri, Turkey. cemalozsaygili@h…. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Macula Lutea, Diabetes Mellitus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To compare the anatomical and functional outcomes of the combination of aflibercept and dexamethasone implant (CT) against aflibercept monotherapy (AM) in treatment-naive diabetic macular edema (DME) patients with serous macular detachment and hyperreflective foci. METHODS: This study included 82 eyes of 82 patients with treatment-naive DME who completed the follow-up period of 12 months. All patients had optical coherence tomography biomarkers of an inflammatory DME phenotype. Patients were consecutively selected and classified into two groups: The CT group consisted of 39 eyes treated with aflibercept therapy and initially combined with a single-dose dexamethasone implant. The AM group consisted of 43 eyes treated with aflibercept alone. The primary outcome measures of the study were the mean reduction of the central macular thickness (CMT) and total macular volume parameters (TMV) and improvement in best-corrected visual acuity. RESULTS: In both groups, the patient characteristics, including age, gender, duration of diabetes, HbA1c levels, phakic percentage, and diabetic retinopathy status were similar (P > 0.05). The mean reduction in CMT and TMV was significantly higher in the CT group compared to the AM group (P < 0.001 and P = 0.002, respectively). In contrast, mean letter gains were not significantly higher (P = 0.240) at the end of the study. In the CT group, 20.5% of patients showed a transient IOP increase, and 18% developed cataracts. In subgroup analysis, the mean letter gain in pseudophakic eyes was significantly higher (12.5 in the CT vs. 9.3 in the AM group, P = 0.027). CONCLUSION: The CT, where inflammation is prominent, can provide faster recovery. The pseudophakic eyes seem to be the ideal patient group for CT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Health Sciences, Kayseri City Training and Research Hospital, Kocasinan, Kayseri, Turkey. cemalozsaygili@hotmail.com.
- University of Health Sciences, Ankara Etlik City Hospital, Yenimahalle, Ankara, Turkey.
Zitieren
APA
Ozsaygılı, C., & Bayram, N. (2024). Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?. International Ophthalmology. https://doi.org/10.1007/s10792-024-02963-8
Vancouver
Ozsaygılı C, Bayram N. Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?. International Ophthalmology. 2024. doi:10.1007/s10792-024-02963-8
BibTeX
@article{Ozsaygl2024,
author = {Ozsaygılı, Cemal and Bayram, Nurettin},
title = {Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?},
journal = {International Ophthalmology},
year = {2024},
doi = {10.1007/s10792-024-02963-8}
}
EUVIMED